Author: Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

This section has been translated automatically.

Ranibizumab is an active ingredient from the group of VEGF inhibitors. Ranibizumab is a humanised recombinant monoclonal antibody fragment (Fab V2) of the monoclonal antibody Bevacizumab. It is produced by means of recombinant DNA from the bacterium Escherichia coli.

Pharmacodynamics (Effect)
This section has been translated automatically.

VEGF combines proteins of different groups, which as signal molecules fulfil different tasks in human vascular tissues. VEGF-A is important for angiogenesis (formation of new vessels) in the eye. Ranibizumab binds to all forms of VEGF-A, thus preventing receptor activation with the downstream signalling cascade. Ranibizumab thus reduces the formation of new retinal vessels and the development of retinal edema (Mantel I et al. 2018).

This section has been translated automatically.

wet age-related macular degeneration, diabetic macular edema, macular edema after vein occlusion

Undesirable effects
This section has been translated automatically.

The most common side effects of ranibizumab are: conjunctival hemorrhage; eye pain; cataracts; floaters; increased intraocular pressure; vitreous detachment; serious side effects are eye infections (endophthalmitis) and retinal detachment.

This section has been translated automatically.

  1. Cai S et al (2017) Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T. Curr Opin Ophthalmol 28:636-643.
  2. Dugel PU et al (2017) Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial. Ophthalmology 124:1296-1304.
  3. Freund KB et al (2015) Treat-and extend regimens with anti-VEGF agents in retinal diseases. Retina. 35:1489–1506
  4. Mantel I et al (2018) Switching between ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration. Surv Ophthalmol 63:638-645.
  5. Moreno TA et al (2016) Ranibizumab (Lucentis) versus Bevacizumab (Avastin) for the Treatment of Age-Related Macular Degeneration: An Economic Disparity of Eye Health. Semin Ophthalmol 31:378-384.
  6. Sangroongruangsri S et al (2018) Comparative efficacy of bevacizumab, ranibizumab, and aflibercept for treatment of macular edema secondary to retinal vein occlusion: a systematic review and network meta-analysis. Expert Rev Clin Pharmacol 11:903-916.
  7. Wang L et l. (2018) Clinical effectiveness of ranibizumab and conbercept for neovascular age-related macular degeneration: a meta-analysis. Drug of Devel Ther 12:3625-3633.


Last updated on: 29.10.2020